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INTRODUCTION:
Glucuronidation, catalyzed by the uridine diphosphate glucuronosyltransferases (UGTs), is an important metabolic pathway for the detoxification and elimination of many endobiotics (bilirubin, bile acids) and xenobiotics (zidovudine, acetaminophen) . UGT enzymes transfer the glucuronic acid moiety from a cofactor uridine 5'-diphosphoglucuronic acid (UDPGA) to hydroxyl, carboxyl or amine groups of aglycone substrates (Tukey and Strassburg, 2004) . The resulting β -glucuronide metabolites are usually water-soluble, less active or toxic and can be readily excreted from the body via bile and urine. At least 17 human UGT isoforms have been identified to date and can be categorized into two subfamilies, UGT1 and UGT2, based on similarities of their amino acid sequences and gene organization (Mackenzie et al., 2005) . UGT enzymes are localized primarily in the endoplasmic reticulum and expressed mainly in the liver, though UGT1A7, UGT1A8, UGT1A10 and UGT2A1 are expressed only in extrahepatic tissues . UGT enzymes have generally been shown to display very broad and overlapping substrate selectivity (Kiang et al., 2005) . Only a limited number of isoform-selective UGT substrates and inhibitors have been identified to date, while no isoformselective UGT inhibitory antibody is available .
UGT-catalyzed glucuronidations are responsible for about one-third of all drugs metabolized by Phase II enzymes (Evans and Relling, 1999) . Aliphatic tertiary amine or aromatic amine functional groups are quite common in drugs, such as in tricyclic antidepressants (TCAs) and anticonvulsants. UGT conjugations of these drugs can result in the formation of quaternary ammonium glucuronide metabolites. The quaternary ammonium glucuronides of a number of TCAs, including amitriptyline, imipramine, clomipramine and trimipramine ( Fig. 1) have been identified as major phase II metabolites in human urine (Luo et al., 1995) . The urinary This article has not been copyedited and formatted. The final version may differ from this version. excretion of amitriptyline N-glucuronide metabolite was 2.5 -21% of the oral dose administered (Breyer-Pfaff et al., 1997) . Human UGT1A3 and UGT1A4 were shown to contribute to the Nglucuronidation of imipramine and amitriptyline (Green et al., 1995 . However, the contribution of UGT1A3 to drug conjugation may be insignificant to overall metabolism as it exhibited very high apparent K m values compared with UGT1A4 Kubota et al., 2007) . Eadie-Hofstee plots of imipramine and amitriptyline N-glucuronide metabolites indicated that more than one enzyme or active site participated in the Nglucuronidation in human liver microsomes (HLM). UGT1A4 was suggested as the low affinity enzyme for conjugations of both drugs while the high affinity enzyme was not identified in these studies (Breyer-Pfaff et al., 1997 Nakajima et al., 2002) .
It was well accepted that only UGT1A3 and UGT1A4 could catalyze quaternary Nglucuronidation reactions until recent reports demonstrated that UGT2B10 catalyzed direct quaternary N-conjugations at the aromatic nitrogen of nicotine, cotinine and nitrosamines with higher affinities than UGT1A4 (Kaivosaari et al., 2007; Chen et al., 2008) . UGT2B10 has been one of the least characterized UGT isoforms because early research indicated no activity towards a large variety of compounds (Jin et al., 1993) . However, newly identified UGT2B10 substrates suggest that this enzyme could be more relevant than previously thought, especially in Nglucuronidation reactions. In the present study, we expressed human UGT2B10 enzyme in Sf9 insect cells and demonstrated that UGT2B10 catalyzes the quaternary N-glucuronidation of TCAs with higher affinity than UGT1A4. UGT2B10 is likely to be a major contributor to the glucuronidation of amitriptyline, imipramine, clomipramine and trimipramine at therapeutic concentrations in vivo. Recombinant baculovirus-containing culture supernatants were harvested (passage 1 viral stock), amplified and titered by using BaculoELISA kits.
High-titer passage 3 stock was used for UGT2B10 protein expression. Sf9 insect cell liquid cultures were grown in Sf-900 II SFM medium at 27°C with orbital shaking at 120 rpm.
Sf9 cells were infected at ~ 1-1.5 x 10 6 viable cells/mL. Cells were infected at a multiplicity of aliphatic N-glucuronide metabolite resemble the aglycone substrate (Hawes, 1998) . The Nglucuronides were generated in HLM incubations at 100 μM of each TCA compound. After evaporation to dryness and reconstitution in 20% methanol, N-glucuronides were quantified using HPLC-UV spectroscopy. The UV spectra were recorded from 256 to 264 nm (encompassing the UV maxima), and calibration curves were prepared using corresponding TCA over a concentration range of 0. 
Michaelis-Menten equation for two-enzyme hyperbolic kinetics:
where V max is apparent maximal velocity and K m is the concentration of substrate at which halfmaximal velocity is achieved. V max2 and K m2 are constants for the second enzyme or binding site.
Hill equation, which describes sigmoidal kinetics:
where S 50 is the substrate concentration resulting in 50% of V max (analogous to the K m in previous equations) and n is Hill coefficient.
Substrate inhibition:
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The biphasic kinetic profile described by Equation 5 is different from that described in Equation
2
. Biphasic kinetics has two distinct phases but does not follow saturation kinetics. At low substrate concentration, the kinetic profile is curved as with hyperbolic kinetics; however, at high substrate concentration, the velocity of the reaction continues to increase, developing a linear, upward slope. CL int2 represents the slope of the linear portion.
For reactions exhibiting Michaelis-Menten, substrate inhibition and biphasic kinetics, intrinsic clearance (CL int ) was calculated as V max /K m . For reactions exhibiting sigmoidal kinetics, maximum clearance (CL max ) was calculated using the following equation (Houston and Kenworthy, 2000) . 
Goodness of fit to kinetic models was assessed from standard error, 95% confidence intervals and r 2 . Kinetic curves were also analyzed using Eadie-Hofstee plots when fitted with different kinetic models. Kinetic constants were reported as the mean ± standard error of the parameter estimated.
Results
Protein Expression. Full-length cDNA of human UGT2B10 was cloned and protein was expressed in Sf9 insect cells. Expression of UGT2B10 was confirmed by immunoblotting analysis using a commercially available anti-UGT2B antibody. According to the manufacturer, the anti-UGT2B antibody was raised against a peptide mapping near the C-terminus of UGT2B
of human origin and therefore could be used for detection of a broad range of UGT2B family members of mouse, rat and human origin by Western Blotting. It also has been successfully used to detect human UGTs 2B4, 2B7, 2B10 and 2B11 by Western blot (Nishiyama et al., 2006) .
UGT2B10 protein exhibited an apparent molecular mass of ~ 51.8 kDa (Fig. 2 ) that was consistent with another report (Uchaipichat et al., 2004) . Microsomes prepared from uninfected Sf9 cells exhibited no cross reactivity to anti-UGT2B antibody.
Quaternary N-Glucuronidation in Recombinant UGTs. Two TCA substrate concentrations, 5 and 50 µM, were used in the activity assays in recombinant UGT1A3, UGT1A4 and UGT2B10. At TCA concentration of 5 µM, UGT1A3 did not exhibit detectable Nglucuronidation activity towards imipramine or trimipramine. Low levels of amitriptyline and clomipramine N-glucuronidation, 3.2 and 0.27 pmol/min/mg, were detected in UGT1A3, respectively. However, glucuronide formation in UGT1A3 was at least 30-fold lower than that observed in UGT1A4 or UGT2B10. UGT2B10-catalyzed imipramine N-glucuronidation was approximately 2-fold more efficient than that catalyzed by UGT1A4. UGT2B10 and UGT1A4 exhibited comparable activity in metabolizing amitriptyline, clomipramine and trimipramine at 5 µM of substrate concentration. (Fig. 3A) .
At 50 µM TCA concentration, UGT1A4 appeared to be the most active human UGT for TCA glucuronidation, while UGT1A3 exhibited the least activity (Fig. 3B) . Results with UGT1A3 are consistent with previous findings, indicating that UGT1A3 is likely insignificant to the overall metabolism of these drugs . UGT2B10-catalyzed imipramine N-glucuronidation was comparable with that catalyzed by UGT1A4, while UGT1A4
was approximately 5-fold more efficient than UGT2B10 in the glucuronidation of amitriptyline, clomipramine and trimipramine (Fig. 3B) .
Kinetics of Quaternary N-Glucuronidation. The kinetics of TCA glucuronidation was characterized in HLM, recombinant UGT2B10 and UGT1A4 (Fig. 4) . Kinetic parameters of glucuronidation for each substrate are shown in Table 1 . Amitriptyline N-glucuronidation by HLM was best described with a two-enzyme Michaelis-Menten kinetics (eq. 2) ( (353 µM) was approximately 136-fold higher than the K m value. The intrinsic clearance for amitriptyline N-glucuronidation by UGT2B10 was more than 10-fold higher than that determined for UGT1A4.
Biphasic kinetics was observed for imipramine N-glucuronidation by HLM (eq. 5) (Fig.   4 ). The high affinity component exhibited apparent K m and V max values of 9.92 µM and 55.7
pmol/min/mg, while the low affinity component was not saturable at 500 μM substrate concentration and showed an apparent CL int of 0.98 µl/min/mg. Imipramine glucuronidation by UGT2B10 exhibited one-enzyme Michaelis-Mention kinetics (eq. 1) (Fig.4) In contrast to the sigmoidal kinetics observed with HLM, trimipramine glucuronidation by UGT2B10 and UGT1A4 exhibited one-enzyme Michaelis-Menten kinetics (eq. 1) (Fig. 4) .
The apparent K m values of trimipramine glucuronidation were 11.2 and 258 µM by UGT2B10 and UGT1A4. HLM exhibited apparent S 50 value of 277 µM, similar as apparent K m value by UGT1A4. The intrinsic clearance for trimipramine glucuronidation by UGT2B10 and UGT1A4
were similar (0.9 and 1.2 µl/min/mg for UGT2B10 and UGT1A4, respectively).
Selective Inhibition of UGT Activities. The inhibitory effects of hecogenin and nicotine on UGT1A4 and UGT2B10 activities were investigated using TCA as substrate at a 5 µM concentration. As shown in Fig. 5A and 89%, 88% and 90% of the glucuronidation of amitriptyline, imipramine, clomipramine and trimipramine by UGT2B10, while exhibited no inhibition of UGT1A4 activities. On the contrary, hecogenin at 100 µM inhibited 83%, 81%, 75% and 83% of the glucuronidation of amitriptyline, imipramine, clomipramine and trimipramine by UGT1A4, while exhibited less than 10% of inhibition of UGT2B10 activities.
The contribution of UGT1A4 and UGT2B10 to glucuronidation of TCAs was assessed in pooled HLM using hecogenin and nicotine as selective inhibitors. As shown in Fig. 6A , at 5 µM TCA concentration, 500 µM of nicotine significantly inhibited 33%, 50%, 36% and 40% of the glucuronidation of amitriptyline, imipramine, clomipramine and trimipramine by HLM.
Hecogenin at 100 µM exhibited no inhibitory effect on amitriptyline glucuronidation, and inhibited 15%, 13% and 32% of glucuronidation of imipramine, clomipramine and trimipramine at 5 µM substrate concentration. At 200 µM TCA concentration (Fig. 6B ), hecogenin at 100 µM significantly inhibited 45%, 75%, 72% and 49% of the glucuronidation of amitriptyline, imipramine, clomipramine and trimipramine by HLM, respectively. On the other hand, 500 µM nicotine did not inhibit TCA glucuronidation by HLM (Fig. 6B) . Addition of hecogenin increased inhibitory effect of nicotine at 5 µM TCA concentration (Fig. 6A ), while addition of nicotine did not increase the inhibitory effect of hecogenin at 200 µM TCA concentration (Fig.   6B ).
Discussion
Human UGT2B10 has been largely considered as an "orphan" UGT isoform until recent findings demonstrated that UGT2B10 was primarily responsible for the quaternary Nglucuronidation of nicotine, cotinine and nitrosamines (Kaivosaari et al., 2007; Chen et al., 2008) . The present study expanded the UGT2B10 substrate list to include a number of aliphatic tertiary amines, amitriptyline, imipramine, clomipramine and trimipramine. These observations may prompt other investigators to consider the importance of UGT2B10 in the metabolism and clearance of xenobiotics for drugs that undergo quaternary N-glucuronidation.
The quaternary N-glucuronides of TCAs were major Phase II metabolites identified in human urine (Luo et al., 1995) . The steady-state plasma concentrations of amitriptyline, imipramine, clomipramine and trimipramine are approximately 0.2, 0.6, 0.2 and 0.2 µM respectively (Reis et al., 2009; Balley and Jatlow, 1976; Musa, 1989) . In present study, the glucuronidation kinetics studied was assessed at a wide concentration range ( clearly demonstrated that UGT2B10 also exhibited higher affinity towards these two drugs than UGT1A4. However, the high affinity component associated with UGT2B10 was probably hidden by the sigmoidal kinetic character observed in HLM. Though the glucuronidation capacity (V max ) by UGT2B10 was lower than that by UGT1A4 for these TCAs, the in vitro clearance was comparable between UGT2B10 and UGT1A4 due to the very high affinity of UGT2B10 to TCAs. The intrinsic clearance of amitriptyline by UGT2B10 was more than 10-fold higher than that by UGT1A4. These results suggested that UGT2B10 was likely to be a high affinity but low capacity enzyme while UGT1A4 was a low affinity but high capacity enzyme in the glucuronidation of amitriptyline, imipramine, clomipramine and trimipramine. These TCA compounds are hydrophobic bases and have been reported to bind non-specifically to HLM and insect cell microsomes (Venkatakrishnan et al., 2000; McLure et al., 2000; Austin et al., 2002) . It would be important to determine non-specific binding of these drugs in the in vitro incubation matrices to improve any extrapolation of the in vitro findings to predict in vivo observations (Obach, 1997) .
In present study, we demonstrated that hecogenin selectively inhibited of UGT1A4 glucuronidation activity towards TCAs at concentration up to 100 µM. Nicotine demonstrated highly selective inhibition toward UGT2B10, and no inhibition towards UGT1A4 activities at concentration up to 500 µM in the in vitro conditions. Though the inhibitory effects of nicotine towards other UGT isoform activities requires further exploration, nicotine could be used as a selective inhibitor in vitro to differentiate UGT1A4 and UGT2B10 activities.
This article has not been copyedited and formatted. The final version may differ from this version. At low TCA concentration, nicotine significantly inhibited their glucuronidation activities in HLM, while hecogenin exhibited no inhibition of amitriptyline glucuronidation and much less inhibition of imipramine, clomipramine and trimipramine glucuronidation. The inhibition profiles at high TCA concentration were opposite to that observed at low TCA concentration, however, considering low therapeutic concentration of these drugs, observations at high TCA concentration might not be relevant in vivo. Similar inhibition profiles were also reported for amitriptyline (Dehal et al., 2001) , where the authors showed that hecogenin significantly to determine mRNA copy numbers of each UGT isoform in human liver and other tissues (Ohno and Nakajin, 2009; Izukawa et al., 2009 In conclusion, this study demonstrated for the first time that UGT2B10 was able to catalyze aliphatic tertiary amines to form quaternary N-glucuronide. This work also revealed that This article has not been copyedited and formatted. The final version may differ from this version. 
